Overlake Medical Center

Summary

Overlake Medical Center is a medical facility located in Bellevue, Washington. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Pancreatic Cancer and other specialties. Overlake Medical Center is involved with conducting 175 clinical trials across 320 conditions. There are 5 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, Kathleen Gibson, MD, and John A. Keech.

Top PIs

Clinical Trials running at Overlake Medical Center

Bladder Cancer

Bladder Carcinoma

Kidney Cancer

Testicular cancer

Esophageal cancer

Lung Cancer

Pancreatic Cancer

Pancreatic Carcinoma

Gastric cancer

Esophageal Adenocarcinoma

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.

Recruiting

2 awards

Phase 3

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Recruiting

1 award

Phase 2

21 criteria